Evidence map›Paper›PMID 20848158›Full record

ReviewCellular and molecular life sciences : CMLS2011

Endothelin.

Yoshifumi Kawanabe, Surya M Nauli

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Reproducibility of cerebrovascular reactivity measurements: A systematic review of neuroimaging techniquesJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Hyperoxia evokes pericyte-mediated capillary constriction.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Yoshifumi KawanabeDepartment of Neurosurgery, Otsu Municipal Hospital, Shiga, Japan. bwh5255725@yahoo.co.jp
Surya M Nauli
Otsu Municipal Hospital · JPUniversity of Toledo · US

Funding

The roles of primary cilia in cardiovascular systemR01DK080640 · NIDDK · UNIVERSITY OF TOLEDO · PI NAULI, SURYA · 2008 to 2012
$1.6M
NIDDK NIH HHS DK080640NIDDK NIH HHS R01 DK080640
6 · The paper itself

Abstract

Endothelin-1 is the most potent vasoconstrictor agent currently identified, and it was originally isolated and characterized from the culture media of aortic endothelial cells. Two other isoforms, termed endothelin-2 and endothelin-3, were subsequently identified, along with structural homologues isolated from the venom of Actractapis engaddensis known as the sarafotoxins. In this review, we will discuss the basic science of endothelins, endothelin-converting enzymes, and endothelin receptors. Only concise background information pertinent to clinical physician is provided. Next we will describe the pathophysiological roles of endothelin-1 in pulmonary arterial hypertension, heart failure, systemic hypertension, and female malignancies, with emphasis on ovarian cancer. The potential intervention with pharmacological therapeutics will be succinctly summarized to highlight the exciting pre-clinical and clinical studies within the endothelin field. Of note is the rapid development of selective endothelin receptor antagonists, which has led to an explosion of research in the field.

Indexed as

Aspartic Acid EndopeptidasesEndothelinsHypertension, PulmonaryMetalloendopeptidasesReceptors, EndothelinCardiovascular DiseasesClinical Trials as TopicEndothelin-Converting EnzymesEndothelin Receptor AntagonistsFamilial Primary Pulmonary HypertensionFemaleHeart FailureHumansOvarian NeoplasmsVasoconstrictionAspartic Acid EndopeptidasesEndothelin-Converting EnzymesEndothelin Receptor AntagonistsEndothelinsMetalloendopeptidasesReceptors, Endothelin

Identifiers

PMID20848158
PMCPMC3141212
OpenAlexW3190984494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.